2.00
0.11 (5.54%)
| Previous Close | 1.90 |
| Open | 1.88 |
| Volume | 2,266,467 |
| Avg. Volume (3M) | 1,778,426 |
| Market Cap | 195,237,312 |
| Price / Sales | 8.31 |
| Price / Book | 18.23 |
| 52 Weeks Range | |
| Earnings Date | 11 Mar 2026 |
| Operating Margin (TTM) | -758.05% |
| Diluted EPS (TTM) | -3.04 |
| Quarterly Revenue Growth (YOY) | 310.40% |
| Total Debt/Equity (MRQ) | 49.88% |
| Current Ratio (MRQ) | 3.08 |
| Operating Cash Flow (TTM) | -208.21 M |
| Levered Free Cash Flow (TTM) | -103.52 M |
| Return on Assets (TTM) | -36.80% |
| Return on Equity (TTM) | -140.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Editas Medicine, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.10 |
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.33% |
| % Held by Institutions | 57.56% |
| 52 Weeks Range | ||
| Median | 3.50 (75.00%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 09 Mar 2026 | 3.50 (75.00%) | Buy | 2.00 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BURKLY LINDA | - | 2.04 | -749 | -1,528 |
| O'NEILL GILMORE NEIL | - | 2.04 | -5,394 | -11,004 |
| PARISON AMY | - | 2.04 | -474 | -967 |
| Aggregate Net Quantity | -6,617 | |||
| Aggregate Net Value ($) | -13,499 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 2.04 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BURKLY LINDA | Officer | 03 Mar 2026 | Sell (-) | 749 | 2.04 | 1,528 |
| PARISON AMY | Officer | 03 Mar 2026 | Sell (-) | 474 | 2.04 | 967 |
| O'NEILL GILMORE NEIL | Officer | 03 Mar 2026 | Sell (-) | 5,394 | 2.04 | 11,004 |
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |